glp-1 shortage update fda semaglutide status january 2025 declares end to Wegovy and Ozempic No Longer on FDA's 📢 FDA has determined the

Ozempic Was Used by Two Million Medicare Part D Enrollees in 2024, Up from Fewer Than 150,000 in 2019 Semaglutide, the GLP-1 drug branded as Ozempic, Rybelsus, and Wegovy, was the most used GLP-1 in 2024

Lithium Polymer (LiPo) batteries have become the preferred power source for a wide range of electronic devices, including remote-controlled vehicles, drones, and various portable gadgets

While preclinical studies and anecdotal evidence suggest potential benefits, the lack of comprehensive clinical trial data limits our understanding of its full therapeutic potential and possible side effects

In the United States, research presented to the Endocrine Society using insurance records from more than 60,000 Americans with type 2 diabetes found roughly four in ten stopped their GLP-1 medication within the first year

Majzoub, Ahmad